|
Published by: Global Markets Direct
Published: Aug. 31, 2012 - 269 Pages
Table of Contents- Introduction
- Global Markets Direct Report Coverage
- Alzheimer's Disease Overview
- Therapeutics Development
- An Overview of Pipeline Products for Alzheimer's Disease
- Alzheimer's Disease Therapeutics under Development by Companies
- Alzheimer's Disease Therapeutics under Investigation by Universities/Institutes
- Late Stage Products
- Comparative Analysis
- Mid Clinical Stage Products
- Comparative Analysis
- Early Clinical Stage Products
- Comparative Analysis
- Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Alzheimer's Disease Therapeutics – Products under Development by Companies
- Alzheimer's Disease Therapeutics – Products under Investigation by Universities/Institutes
- Companies Involved in Alzheimer's Disease Therapeutics Development
- Bristol-Myers Squibb Company
- Baxter International Inc.
- Boehringer Ingelheim GmbH
- F. Hoffmann-La Roche Ltd.
- Abbott Laboratories
- Biogen Idec Inc.
- NsGene A/S
- Sanofi-Aventis
- AstraZeneca PLC
- Eli Lilly and Company
- GlaxoSmithKline plc
- Genentech, Inc.
- Merck & Co., Inc.
- United Biomedical, Inc.
- Taisho Pharmaceutical Co., Ltd.
- Euroscreen S.A.
- Applied NeuroSolutions, Inc.
- ExonHit Therapeutics SA
- Avineuro Pharmaceuticals, Inc.
- Nanotherapeutics, Inc.
- Senexis Limited
- Novartis AG
- Aphios Corporation
- EnVivo Pharmaceuticals
- Astellas Pharma Inc.
- Chiesi Farmaceutici SpA
- Daewoong Pharmaceutical Co., Ltd.
- Eisai Co., Ltd.
- Elan Corporation, plc
- H Lundbeck A/S
- Kowa Company, Ltd.
- Les Laboratoires Servier
- Merz GmbH & Co. KGaA
- Octapharma AG
- Orion Corporation
- Pfizer Inc.
- Toyama Chemical Co. Ltd
- VIVUS, Inc.
- Hadasit Medical Research Services & Development Ltd
- Addex Pharmaceuticals
- Evotec Aktiengesellschaft
- Anavex Life Sciences Corp.
- Neuralstem, Inc.
- Amicus Therapeutics, Inc.
- Genfit
- AVANIR Pharmaceuticals
- BELLUS Health Inc
- ReGenX Biosciences, LLC
- Neuro-Hitech, Inc.
- Nymox Pharmaceutical Corporation
- Osta Biotechnologies Inc.
- Cortex Pharmaceuticals, Inc.
- Critical Outcome Technologies Inc.
- ACADIA Pharmaceuticals Inc.
- ProteoTech, Inc.
- WhanIn Pharmaceutical Co., Ltd.
- Phytopharm Plc
- Prana Biotechnology Limited
- Biotie Therapies Corp.
- Transition Therapeutics Inc.
- Allon Therapeutics Inc.
- Neurim Pharmaceuticals (1991) Ltd.
- Samaritan Pharmaceuticals, Inc.
- Theravance, Inc.
- Suven Life Sciences Ltd.
- Galapagos NV
- MediPost Co., Ltd.
- Proximagen Neuroscience plc.
- Newron Pharmaceuticals S.p.A.
- Raptor Pharmaceuticals Corp.
- Mithridion, Inc.
- Teikoku Pharma USA, Inc.
- Xel Pharmaceuticals, Inc.
- Oryzon
- TauRx Therapeutics Ltd
- Ceregene, Inc.
- CoMentis, Inc.
- AC Immune SA
- Humanetics Corporation
- Noscira, S.A.
- Accera, Inc.
- Sonexa Therapeutics, Inc.
- Bio-Link
- D-Pharm Ltd.
- StemCells, Inc.
- Axxam SpA
- Probiodrug AG
- Snowdon Inc.
- Domain Therapeutics
- Wellstat Therapeutics Corporation
- BIOALVO S.A.
- IMMD Inc.
- CoLucid Pharmaceuticals, Inc.
- Metabolic Solutions Development Co.
- Hawthorn Pharmaceuticals, Inc.
- BioArctic Neuroscience AB
- Affichem
- Adamas Pharmaceuticals, Inc.
- QR Pharma, Inc.
- NeuroNascent, Inc.
- Siena Biotech S.p.A.
- Virobay Inc.
- SeneXta Therapeutics SA
- KineMed, Inc.
- Intellect Neurosciences, Inc.
- Xencor, Inc.
- Adeona Pharmaceuticals, Inc.
- Intra-Cellular Therapies, Inc.
- Targacept, Inc.
- N-Gene Research Laboratories, Inc.
- RemeGenix, Inc.
- AB Science
- Vitae Pharmaceuticals, Inc.
- Tautatis Incorporated
- Krenitsky Pharmaceuticals Inc.
- Lipopharma
- Medisyn Technologies, Inc.
- PALUMED S.A.
- M's Science Corporation
- NasVax Ltd.
- BrainCells Inc.
- Stelic Institute & Co.
- EndoCeutics, Inc.
- aFraxis Inc.
- Pharnext SAS
- PharmatrophiX, Inc.
- Satori Pharmaceuticals Inc.
- Heptares Therapeutics Ltd.
- Signum Biosciences, Inc.
- Neuraltus Pharmaceuticals, Inc.
- ArmaGen Technologies, Inc.
- BioChromix Pharma AB
- Archer Pharmaceuticals, Inc.
- Varinel, Inc.
- Cognosci, Inc.
- Reviva Pharmaceuticals Inc.
- RaQualia Pharma Inc.
- PharmaNeuroBoost N.V.
- Alzheimer's Disease – Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Drug Profiles
- Solanezumab - Drug Profile
- Aricept - Drug Profile
- Vitamin E + Selenium - Drug Profile
- Thalidomide - Drug Profile
- SK-PC-B70M - Drug Profile
- Citalopram - Drug Profile
- Vitamin E + Namenda - Drug Profile
- Doxycycline + Rifampicin - Drug Profile
- Doxycycline - Drug Profile
- Rifampicin - Drug Profile
- Valproate - Drug Profile
- WIN-026 - Drug Profile
- ARC029 - Drug Profile
- Gammagard Liquid - Drug Profile
- Arimenda - Drug Profile
- Memantine + Vitamin D3 - Drug Profile
- BVF-040 - Drug Profile
- Femivia - Drug Profile
- Alzheimer's Disease Therapeutics – Drug Profile Updates
- Alzheimer's Disease Therapeutics – Discontinued Products
- Alzheimer's Disease Therapeutics - Dormant Products
- Alzheimer's Disease – Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products Under Development for Alzheimer's Disease, H2 2012
- Products under Development for Alzheimer's Disease – Comparative Analysis, H2 2012
- Number of Products under Development by Companies, H2 2012
- Number of Products under Development by Companies, H2 2012 (Contd..1)
- Number of Products under Development by Companies, H2 2012 (Contd..2)
- Number of Products under Development by Companies, H2 2012 (Contd..3)
- Number of Products under Development by Companies, H2 2012 (Contd..4)
- Number of Products under Development by Companies, H2 2012 (Contd..5)
- Number of Products under Development by Companies, H2 2012 (Contd..6)
- Number of Products under Development by Companies, H2 2012 (Contd..7)
- Number of Products under Development by Companies, H2 2012 (Contd..8)
- Number of Products under Development by Companies, H2 2012 (Contd..9)
- Number of Products under Development by Companies, H2 2012 (Contd..10)
- Number of Products under Development by Companies, H2 2012 (Contd..11)
- Number of Products under Investigation by Universities/Institutes, H2 2012
- Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1)
- Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..2)
- Comparative Analysis by Late Stage Development, H2 2012
- Comparative Analysis by Mid Clinical Stage Development, H2 2012
- Comparative Analysis by Early Clinical Stage Development, H2 2012
- Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012
- Products under Development by Companies, H2 2012
- Products under Development by Companies, H2 2012 (Contd..1)
- Products under Development by Companies, H2 2012 (Contd..2)
- Products under Development by Companies, H2 2012 (Contd..3)
- Products under Development by Companies, H2 2012 (Contd..4)
- Products under Development by Companies, H2 2012 (Contd..5)
- Products under Development by Companies, H2 2012 (Contd..6)
- Products under Development by Companies, H2 2012 (Contd..7)
- Products under Development by Companies, H2 2012 (Contd..8)
- Products under Development by Companies, H2 2012 (Contd..9)
- Products under Development by Companies, H2 2012 (Contd..10)
- Products under Development by Companies, H2 2012 (Contd..11)
- Products under Development by Companies, H2 2012 (Contd..12)
- Products under Development by Companies, H2 2012 (Contd..13)
- Products under Development by Companies, H2 2012 (Contd..14)
- Products under Development by Companies, H2 2012 (Contd..15)
- Products under Development by Companies, H2 2012 (Contd..16)
- Products under Development by Companies, H2 2012 (Contd..17)
- Products under Development by Companies, H2 2012 (Contd..18)
- Products under Development by Companies, H2 2012 (Contd..19)
- Products under Investigation by Universities/Institutes, H2 2012
- Products under Investigation by Universities/Institutes, H2 2012 (Contd..1)
- Products under Investigation by Universities/Institutes, H2 2012 (Contd..2)
- Bristol-Myers Squibb Company, H2 2012
- Baxter International Inc., H2 2012
- Boehringer Ingelheim GmbH, H2 2012
- F. Hoffmann-La Roche Ltd., H2 2012
- Abbott Laboratories, H2 2012
- Biogen Idec Inc., H2 2012
- NsGene A/S, H2 2012
- Sanofi-Aventis, H2 2012
- AstraZeneca PLC, H2 2012
- Eli Lilly and Company, H2 2012
- GlaxoSmithKline plc, H2 2012
- Genentech, Inc., H2 2012
- Merck & Co., Inc., H2 2012
- United Biomedical, Inc., H2 2012
- Taisho Pharmaceutical Co., Ltd., H2 2012
- Euroscreen S.A., H2 2012
- Applied NeuroSolutions, Inc., H2 2012
- ExonHit Therapeutics SA, H2 2012
- Avineuro Pharmaceuticals, Inc., H2 2012
- Nanotherapeutics, Inc., H2 2012
- Senexis Limited, H2 2012
- Novartis AG, H2 2012
- Aphios Corporation, H2 2012
- EnVivo Pharmaceuticals, H2 2012
- Astellas Pharma Inc., H2 2012
- Chiesi Farmaceutici SpA, H2 2012
- Daewoong Pharmaceutical Co., Ltd., H2 2012
- Eisai Co., Ltd., H2 2012
- Elan Corporation, plc, H2 2012
- H Lundbeck A/S, H2 2012
- Kowa Company, Ltd., H2 2012
- Les Laboratoires Servier, H2 2012
- Merz GmbH & Co. KGaA, H2 2012
- Octapharma AG, H2 2012
- Orion Corporation, H2 2012
- Pfizer Inc., H2 2012
- Toyama Chemical Co. Ltd, H2 2012
- VIVUS, Inc., H2 2012
- Hadasit Medical Research Services & Development Ltd, H2 2012
- Addex Pharmaceuticals, H2 2012
- Evotec Aktiengesellschaft, H2 2012
- Anavex Life Sciences Corp., H2 2012
- Neuralstem, Inc., H2 2012
- Amicus Therapeutics, Inc., H2 2012
- Genfit, H2 2012
- AVANIR Pharmaceuticals, H2 2012
- BELLUS Health Inc, H2 2012
- ReGenX Biosciences, LLC, H2 2012
- Neuro-Hitech, Inc., H2 2012
- Nymox Pharmaceutical Corporation, H2 2012
- Osta Biotechnologies Inc., H2 2012
- Cortex Pharmaceuticals, Inc., H2 2012
- Critical Outcome Technologies Inc., H2 2012
- ACADIA Pharmaceuticals Inc., H2 2012
- ProteoTech, Inc., H2 2012
- WhanIn Pharmaceutical Co., Ltd., H2 2012
- Phytopharm Plc, H2 2012
- Prana Biotechnology Limited, H2 2012
- Biotie Therapies Corp., H2 2012
- Transition Therapeutics Inc., H2 2012
- Allon Therapeutics Inc., H2 2012
- Neurim Pharmaceuticals (1991) Ltd., H2 2012
- Samaritan Pharmaceuticals, Inc., H2 2012
- Theravance, Inc., H2 2012
- Suven Life Sciences Ltd., H2 2012
- Galapagos NV, H2 2012
- MediPost Co., Ltd., H2 2012
- Proximagen Neuroscience plc., H2 2012
- Newron Pharmaceuticals S.p.A., H2 2012
- Raptor Pharmaceuticals Corp., H2 2012
- Mithridion, Inc., H2 2012
- Teikoku Pharma USA, Inc., H2 2012
- Xel Pharmaceuticals, Inc., H2 2012
- Oryzon, H2 2012
- TauRx Therapeutics Ltd, H2 2012
- Ceregene, Inc., H2 2012
- CoMentis, Inc., H2 2012
- AC Immune SA, H2 2012
- Humanetics Corporation, H2 2012
- Noscira, S.A., H2 2012
- Accera, Inc., H2 2012
- Sonexa Therapeutics, Inc., H2 2012
- Bio-Link, H2 2012
- D-Pharm Ltd., H2 2012
- StemCells, Inc., H2 2012
- Axxam SpA, H2 2012
- Probiodrug AG, H2 2012
- Snowdon Inc., H2 2012
- Domain Therapeutics, H2 2012
- Wellstat Therapeutics Corporation, H2 2012
- BIOALVO S.A., H2 2012
- IMMD Inc., H2 2012
- CoLucid Pharmaceuticals, Inc., H2 2012
- Metabolic Solutions Development Co., H2 2012
- Hawthorn Pharmaceuticals, Inc., H2 2012
- BioArctic Neuroscience AB, H2 2012
- Affichem, H2 2012
- Adamas Pharmaceuticals, Inc., H2 2012
- QR Pharma, Inc., H2 2012
- NeuroNascent, Inc., H2 2012
- Siena Biotech S.p.A., H2 2012
- Virobay Inc., H2 2012
- SeneXta Therapeutics SA, H2 2012
- KineMed, Inc., H2 2012
- Intellect Neurosciences, Inc., H2 2012
- Xencor, Inc., H2 2012
- Adeona Pharmaceuticals, Inc., H2 2012
- Intra-Cellular Therapies, Inc., H2 2012
- Targacept, Inc., H2 2012
- N-Gene Research Laboratories, Inc., H2 2012
- RemeGenix, Inc., H2 2012
- AB Science, H2 2012
- Vitae Pharmaceuticals, Inc., H2 2012
- Tautatis Incorporated, H2 2012
- Krenitsky Pharmaceuticals Inc., H2 2012
- Lipopharma, H2 2012
- Medisyn Technologies, Inc., H2 2012
- PALUMED S.A., H2 2012
- M's Science Corporation, H2 2012
- NasVax Ltd., H2 2012
- BrainCells Inc., H2 2012
- Stelic Institute & Co., H2 2012
- EndoCeutics, Inc., H2 2012
- aFraxis Inc., H2 2012
- Pharnext SAS, H2 2012
- PharmatrophiX, Inc., H2 2012
- Satori Pharmaceuticals Inc., H2 2012
- Heptares Therapeutics Ltd., H2 2012
- Signum Biosciences, Inc., H2 2012
- Neuraltus Pharmaceuticals, Inc., H2 2012
- ArmaGen Technologies, Inc., H2 2012
- BioChromix Pharma AB, H2 2012
- Archer Pharmaceuticals, Inc., H2 2012
- Varinel, Inc., H2 2012
- Cognosci, Inc., H2 2012
- Reviva Pharmaceuticals Inc., H2 2012
- RaQualia Pharma Inc., H2 2012
- PharmaNeuroBoost N.V., H2 2012
- Assessment by Monotherapy Products, H2 2012
- Assessment by Combination Products, H2 2012
- Assessment by Stage and Route of Administration, H2 2012
- Assessment by Stage and Molecule Type, H2 2012
- Alzheimer's Disease Therapeutics – Drug Profile Updates
- Alzheimer's Disease Therapeutics – Discontinued Products
- Alzheimer's Disease Therapeutics – Discontinued Products (Contd..1)
- Alzheimer's Disease Therapeutics – Discontinued Products (Contd..2)
- Alzheimer's Disease Therapeutics – Discontinued Products (Contd..3)
- Alzheimer's Disease Therapeutics – Discontinued Products (Contd..4)
- Alzheimer's Disease Therapeutics – Discontinued Products (Contd..5)
- Alzheimer's Disease Therapeutics – Discontinued Products (Contd..6)
- Alzheimer's Disease Therapeutics – Dormant Products
- Alzheimer's Disease Therapeutics – Dormant Products (Contd..1)
- Alzheimer's Disease Therapeutics – Dormant Products (Contd..2)
- Alzheimer's Disease Therapeutics – Dormant Products (Contd..3)
- Alzheimer's Disease Therapeutics – Dormant Products (Contd..4)
- Alzheimer's Disease Therapeutics – Dormant Products (Contd..5)
- Alzheimer's Disease Therapeutics – Dormant Products (Contd..6)
- Alzheimer's Disease Therapeutics – Dormant Products (Contd..7)
- Alzheimer's Disease Therapeutics – Dormant Products (Contd..8)
- Alzheimer's Disease Therapeutics – Dormant Products (Contd..9)
- Alzheimer's Disease Therapeutics – Dormant Products (Contd..10)
- Alzheimer's Disease Therapeutics – Dormant Products (Contd..11)
- Alzheimer's Disease Therapeutics – Dormant Products (Contd..12)
- Alzheimer's Disease Therapeutics – Dormant Products (Contd..13)
- Alzheimer's Disease Therapeutics – Dormant Products (Contd..14)
- List of Figures
- Number of Products under Development for Alzheimer's Disease, H2 2012
- Products under Development for Alzheimer's Disease – Comparative Analysis, H2 2012
- Products under Development by Companies, H2 2012
- Products under Investigation by Universities/Institutes, H2 2012
- Late Stage Products, H2 2012
- Mid Clinical Stage Products, H2 2012
- Early Clinical Stage Products, H2 2012
- Discovery and Pre-Clinical Stage Products, H2 2012
- Assessment by Monotherapy Products, H2 2012
- Assessment by Combination Products, H2 2012
- Assessment by Route of Administration, H2 2012
- Assessment by Stage and Route of Administration, H2 2012
- Assessment by Molecule Type, H2 2012
- Assessment by Stage and Molecule Type, H2 2012
AbstractAlzheimer's Disease – Pipeline Review, H2 2012
Summary
Global Markets Direct’s, 'Alzheimer's Disease - Pipeline Review, H2 2012', provides an overview of the Alzheimer's Disease therapeutic pipeline. This report provides information on the therapeutic development for Alzheimer's Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Alzheimer's Disease. 'Alzheimer's Disease - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope- A snapshot of the global therapeutic scenario for Alzheimer's Disease.
- A review of the Alzheimer's Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Alzheimer's Disease pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy- Identify and understand important and diverse types of therapeutics under development for Alzheimer's Disease.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Alzheimer's Disease pipeline depth and focus of Alzheimer's Disease therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Get full details about this report >>
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
